COMPARATIVE ANALYSIS OF AGING AND SENESCENCE-RELATED MOLECULAR SIGNATURES IN YOUNG AND ELDERLY GLIOBLASTOMA PATIENTS



Gravina, T.; ^(1,2) Favero, F.; ^(1,2) Centonze, S.; ^(1,2) Orso, F.; ⁽¹⁾ Pelicci, G.; ^(1,3) and Corà, D. ^(1,2)

(1) Department of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.

(2) Center for Translational Research on Allergic and Autoimmune Diseases (CAAD), University of PiemonteOrientale, 28100 Novara, Italy.

(3) Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.



Glioblastoma (GBM) is a highly malignant and fatal type of adult diffuse glioma that originates from neuroglial progenitor cells, and it has a remarkable ability to infiltrate normal brain parenchyma. Despite being a rare tumor, it is the most common Central Nervous System (CNS) malignancy. The median age at diagnosis is 65 years, indicating that GBM predominantly affects older adults, although rare cases also occur in younger individuals. In this study, we present a bioinformatics analysis aimed at identifying differences between younger and older GBM patient groups by analyzing RNA-Seq data and metadata from the TCGA cohort, as reported by Wang et al. (2021).



METHODS



RESULTS

Differentially expressed genes (DEGs)



Heatmap showing the unsupervised hierarchical clustering of 126 DEGs (Young vs Old)



GSEA results





Gene Set Enrichment Analysis (GSEA)

considering aging (https://agingsignature.webhosting.rug.nl) and senescence (SAUL_SEN - GSEA M45803) signatures. (Young vs Old; NES >1; FDR < 0.05)

Ó	5,000	10,000	15,000	20,000	25,000	30,000	35,000	40,000	45,000	ke	o	5,000	10,000	15,000	20,000	25,000	30,000	35,000	40,00
			Ran	ik in Oro	dered D)ataset			Rai	Rank in Ordered Dataset									
-	- Enrichr	nent pro	ofile —	Hits	— Rar	nking m	etric so	ores			-	Enrichm	ent pro	file —	Hits	— Rar	nking m	etric so	ores

REFERENCE:

Wang, L. B., Karpova, A., Gritsenko, M. A., Kyle, J. E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J. H., Hong, R., Stathias, V., Cornwell, M., Petralia, F., Wu, Y., Reva, B., Krug, K., Pugliese, P., Kawaler, E., Olsen, L. K., Liang, W. W., ... Clinical Proteomic Tumor Analysis Consortium (2021). Proteogenomic andmetabolomic characterization of human glioblastoma. Cancer cell, 39(4), 509–528.e20

(E) 0.35

0.30 0.30 0.25 0.20

0.15

0.10 0.05 0.00

-0.5

-1.0

Rank

matrix from



40.000 45.000